6 Drinks to Reduce Fat

1. Green Tea

2. Lemon Water

3. Green Vegetable Juice

4. Ginger Tea

5. Fenugreek Water

6. Amla Juice and Warm Water

Life Fun: Discover six effective drinks to reduce fat and boost metabolism, including green tea and lemon water, known for their ability to aid digestion and suppress cravings.

A weight-loss drug has shown to be able to reduce risk of heart attacks and improving overall cardiovascular health in adults across the UK, a new study has claimed.

The study found that participants taking the medication semaglutide, the active ingredient in brands including Wegovy and Ozempic, had a 20 per cent&nbsp;lower risk of heart attack, stroke or death due to cardiovascular disease.

Also read:&nbsp;<a href="https://www.wionews.com/world/watch-white-house-corridors-echo-with-saare-jahan-se-accha-as-attendees-dig-on-pani-puris-721273">Watch: White House corridors echo with 'Saare Jahan Se Accha' as attendees dig on pani puris</a>

The study, presented at the European Congress of Obesity (ECO) and led by researchers at University College London, found semaglutide improved cardiovascular health in participants, independent of starting weight or weight loss amount.

Those with mild obesity or who have lost only a small amount of weight could have an improved cardiovascular outcome.

“Findings show the drug should be regularly prescribed to treat cardiovascular illnesses, and that millions of people across the UK could be taking the medication in the next few years," said&nbsp;Prof John Deanfield, the director of the National Institute for Cardiovascular Outcomes Research and the lead author of the study.

“This drug really is a gamechanger, as study suggests that here are potentially substitute mechanisms for that improved cardiovascular outcome with semaglutide beyond weight loss. Something else is going on that benefits the cardiovascular system.”.

The study examined 17,604 adults aged 45 and over with a body mass index of over 27 from across 41 countries. The participants, who had experienced a cardiovascular event such as a heart attack, were prescribed either a 2.5mg weekly dose of semaglutide or a placebo for an average period of 40 months.

Also read:&nbsp;<a href="https://www.wionews.com/world/watch-influencers-big-yawn-goes-wrong-jaw-locked-wide-open-721159">WATCH | Influencer's big yawn goes wrong, jaw locked wide open!</a>

Of them, 8,803 participants who received semaglutide treatment&nbsp;had a lower risk of cardiovascular events, compared to the placebo group of 8,801 participants.

Specifically, 569 or 6.5% of those taking semaglutide experienced a primary cardiovascular end-point event, such as a heart attack, whereas in the placebo group, the figure stood at 701 or 8%.

The finding is significant because semaglutide, sold under the brand name Wegovy, has been approved for weight loss on the NHS since 2023.

The study claims that this weight-loss medication may offer other cardiovascular benefits, potentially expanding its role in improving overall health outcomes.

Deanfield said, “In the 1990s, statins&nbsp;– drugs that lower cholesterol – were considered a medical breakthrough and revolutionary in treating cardiology practice. Semaglutide could be seen as similarly groundbreaking in regarding to improving cardiovascular health."

According to the British Heart Foundation, approximately 7.6 million people in the UK are living with heart or circulatory disease.

Also read:&nbsp;<a href="https://www.wionews.com/science/new-protein-gel-breaks-down-alcohol-in-gastrointestinal-tract-converts-into-harmless-acetic-acid-721205">Drink without hangover? Scientists create gel that can make alcohol harmless to the human body</a>

However, another study found that participants who were advised semaglutide lost an average of 10.2% of body weight and 7.7cm from their waist over a four-year period, while the participants in the placebo group lost 1.5% of body weight and 1.3cm from the waist.

(With inputs from agencies)

A weight-loss drug has shown to be able to reduce risk of heart attacks and improving overall cardiovascular health in adults across the UK, a new study has claimed.

A weight-loss drug has shown to be able to reduce risk of heart attacks and improving overall cardiovascular health in adults across the UK, a new study has claimed. The study found that participants taking the medication semaglutide, the active ingredient in brands including Wegovy and Ozempic, had a 20 per cent lower risk of heart attack, stroke or death due to cardiovascular disease. Also read: Watch: White House corridors echo with 'Saare Jahan Se Accha' as attendees dig on pani puris The study, presented at the European Congress of Obesity (ECO) and led by researchers at University College London, found semaglutide improved cardiovascular health in participants, independent of starting weight or weight loss amount. Those with mild obesity or who have lost only a small amount of weight could have an improved cardiovascular outcome. “Findings show the drug should be regularly prescribed to treat cardiovascular illnesses, and that millions of people across the UK could be taking the medication in the next few years," said Prof John Deanfield, the director of the National Institute for Cardiovascular Outcomes Research and the lead author of the study. “This drug really is a gamechanger, as study suggests that here are potentially substitute mechanisms for that improved cardiovascular outcome with semaglutide beyond weight loss. Something else is going on that benefits the cardiovascular system.”. The study examined 17,604 adults aged 45 and over with a body mass index of over 27 from across 41 countries. The participants, who had experienced a cardiovascular event such as a heart attack, were prescribed either a 2.5mg weekly dose of semaglutide or a placebo for an average period of 40 months. Also read: WATCH | Influencer's big yawn goes wrong, jaw locked wide open! Of them, 8,803 participants who received semaglutide treatment had a lower risk of cardiovascular events, compared to the placebo group of 8,801 participants. Specifically, 569 or 6.5% of those taking semaglutide experienced a primary cardiovascular end-point event, such as a heart attack, whereas in the placebo group, the figure stood at 701 or 8%. The finding is significant because semaglutide, sold under the brand name Wegovy, has been approved for weight loss on the NHS since 2023. The study claims that this weight-loss medication may offer other cardiovascular benefits, potentially expanding its role in improving overall health outcomes. Deanfield said, “In the 1990s, statins – drugs that lower cholesterol – were considered a medical breakthrough and revolutionary in treating cardiology practice. Semaglutide could be seen as similarly groundbreaking in regarding to improving cardiovascular health." According to the British Heart Foundation, approximately 7.6 million people in the UK are living with heart or circulatory disease. Also read: Drink without hangover? Scientists create gel that can make alcohol harmless to the human body However, another study found that participants who were advised semaglutide lost an average of 10.2% of body weight and 7.7cm from their waist over a four-year period, while the participants in the placebo group lost 1.5% of body weight and 1.3cm from the waist. (With inputs from agencies)

Weight loss chemical in Ozempic, Wegovy may reduce heart attack risk by 20%: Study

Weight loss options are expanding rapidly. A new study presents&nbsp;potential findings for a non-surgical obesity treatment. This procedure involves controlled burning of a portion of the stomach's mucus lining.

The participants in the small trial saw an average weight loss of 8%&nbsp;from their starting weight, along with a notable decrease in hunger.

The process is known as endoscopic mucosal ablation, which is a method already used to remove precancerous or other unusual bits of tissue from the digestive tract.&nbsp;

Also read:&nbsp;<a href="https://www.wionews.com/science/a-tiny-section-of-human-brain-reveals-astounding-57000-cells-150mn-neural-connections-719907">A tiny section of human brain reveals astounding 57,000 cells, 150mn neural connections</a>

In the process, patients first drink a fluid in order to protect the stomach’s tissues, then doctors&nbsp;send an endoscope down through the esophagus to the uppermost portion of the stomach, also called the gastric fundus.&nbsp;

Once there, the endoscope will burn the moist, inner lining of the fundus where mucus is produced.

The key to this procedure lies in the fundus, a part of the stomach responsible for a significant portion of our hunger pangs. This area is the primary producer of ghrelin, a hormone that signals hunger when our stomach is&nbsp;empty. Conversely, ghrelin levels decrease after eating. The goal is to safely reduce hunger by burning a portion of the fundus lining, thereby destroying enough ghrelin-producing cells to promote lasting weight loss.

Researchers running the first-in-human trial of this method announced their early results at the academic conference Digestive Disease Week.

Also read:&nbsp;<a href="https://www.wionews.com/trending/uk-woman-gets-more-than-half-a-million-pounds-payout-after-rushed-childbirth-left-her-with-stoma-and-ptsd-719741">UK woman gets more than half a million pounds payout after 'rushed' childbirth left her with stoma and PTSD</a>

Ten patients living with obesity, all women, took part in the trial. On average, they lost 7.7% of their body weight and experienced a more than 40% reduction in fasting ghrelin levels. Participants’ average level of self-reported hunger also dropped by a third, while their stomach’s capacity for food and drink decreased by 42%.

It's important to note that this is a very early study with only a few participants. The results haven't been reviewed by other scientists yet, so more research is needed before getting too excited.&nbsp;

Also read:&nbsp;<a href="https://www.wionews.com/world/parasitic-worm-once-ate-a-part-of-rfk-jrs-brain-heres-how-it-infects-the-brain-719673">Parasitic worm once ate 'a part of' RFK Jr's brain. Here's how that might happen to anyone</a>

“This non-surgical procedure can smooth the progress of weight loss and significantly control hunger,. It may be a suitable alternative for those who are ineligible for or hesitant about medications like Wegovy or Ozempic, or bariatric surgery,” said study researcher Christopher McGowan, MD, a gastroenterologist and medical director of True You Weight Loss, a North Carolina clinic, in a statement released by Digestive Disease Week.

(With inputs from agencies)

Weight loss options are expanding rapidly. A new study presents potential findings for a non-surgical obesity treatment. This procedure involves controlled burning of a portion of the stomach's mucus lining.

Weight loss options are expanding rapidly. A new study presents potential findings for a non-surgical obesity treatment. This procedure involves controlled burning of a portion of the stomach's mucus lining. The participants in the small trial saw an average weight loss of 8% from their starting weight, along with a notable decrease in hunger. The process is known as endoscopic mucosal ablation, which is a method already used to remove precancerous or other unusual bits of tissue from the digestive tract. Also read: A tiny section of human brain reveals astounding 57,000 cells, 150mn neural connections In the process, patients first drink a fluid in order to protect the stomach’s tissues, then doctors send an endoscope down through the esophagus to the uppermost portion of the stomach, also called the gastric fundus. Once there, the endoscope will burn the moist, inner lining of the fundus where mucus is produced. The key to this procedure lies in the fundus, a part of the stomach responsible for a significant portion of our hunger pangs. This area is the primary producer of ghrelin, a hormone that signals hunger when our stomach is empty. Conversely, ghrelin levels decrease after eating. The goal is to safely reduce hunger by burning a portion of the fundus lining, thereby destroying enough ghrelin-producing cells to promote lasting weight loss. Researchers running the first-in-human trial of this method announced their early results at the academic conference Digestive Disease Week. Also read: UK woman gets more than half a million pounds payout after 'rushed' childbirth left her with stoma and PTSD Ten patients living with obesity, all women, took part in the trial. On average, they lost 7.7% of their body weight and experienced a more than 40% reduction in fasting ghrelin levels. Participants’ average level of self-reported hunger also dropped by a third, while their stomach’s capacity for food and drink decreased by 42%. It's important to note that this is a very early study with only a few participants. The results haven't been reviewed by other scientists yet, so more research is needed before getting too excited. Also read: Parasitic worm once ate 'a part of' RFK Jr's brain. Here's how that might happen to anyone “This non-surgical procedure can smooth the progress of weight loss and significantly control hunger,. It may be a suitable alternative for those who are ineligible for or hesitant about medications like Wegovy or Ozempic, or bariatric surgery,” said study researcher Christopher McGowan, MD, a gastroenterologist and medical director of True You Weight Loss, a North Carolina clinic, in a statement released by Digestive Disease Week. (With inputs from agencies)

Non-surgical weight loss trial shows promising results

Drugmaker Novo Nordisk has overtaken the French luxury group LVMH to become Europe's most valuable company. This comes a day after Novo Nordisk launched his weight loss drug Wegovy in the UK. Has health become the new luxury?

Gravitas: Wegovy maker beats LVMH as Europe's most valuable firm

weightloss

Weightloss, News on Weightloss, stories on Weightloss, articles on Weightloss, Weightloss stories at Wion, Weightloss news, Weightloss latest news